NKTR250117P500
- 0.04
- 0.000.00%
Nektar Therapeutics Newsroom
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Oppenheimer Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $7
Nektar Therapeutics Analyst Ratings
Piper Sandler Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $7
BTIG Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $4
Nektar Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Nektar Therapeutics Analyst Ratings
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
Nektar Therapeutics Analyst Ratings
Nektar Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
Mizuho Reiterates Neutral on Nektar Therapeutics, Maintains $6 Price Target
Nektar Therapeutics Analyst Ratings
Mizuho Securities Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)
SVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
Jefferies Upgrades Nektar Therapeutics (NKTR) to a Hold
Mizuho Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)